HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

valyl(4)-glutaminyl(5)- desmopressin

has both antiangiogenesis and antineoplastic activities

Also Known As:

desmopressin, valyl(4)-glutaminyl(5)-; (V(4)Q(5))dDAVP; desmopressin, Val(4)-Gln(5)-

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Peptide Hormones: 1347
    - Pituitary Hormones: 601
      - Posterior Pituitary Hormones: 176
        Vasopressins: 9692
        Arginine Vasopressin: 2491
        Deamino Arginine Vasopressin: 2782
        valyl(4)-glutaminyl(5)- desmopressin: 2
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Nerve Tissue Proteins: 2
    - Neuropeptides: 6772
      - Vasopressins: 9692
        Arginine Vasopressin: 2491
        Deamino Arginine Vasopressin: 2782
        valyl(4)-glutaminyl(5)- desmopressin: 2
- Peptides: 82426

Experts

1.	Alonso, Daniel F: 2 articles (01/2016 - 12/2011)
2.	Garona, Juan: 2 articles (01/2016 - 12/2011)
3.	Gomez, Daniel E: 2 articles (01/2016 - 12/2011)
4.	Ripoll, Giselle V: 2 articles (01/2016 - 12/2011)
5.	Pastrian, Maria B: 1 article (01/2016)
6.	Pifano, Marina: 1 article (01/2016)
7.	Cascone, Osvaldo: 1 article (12/2011)
8.	Ciccia, Graciela N: 1 article (12/2011)
9.	Iannucci, Nancy B: 1 article (12/2011)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2016 - "In vivo antitumour efficacy of [V(4)Q(5)]dDAVP addition to chemotherapy was first evaluated using the triple-negative MDA-MB-231 breast cancer xenograft model. " 01/01/2016 - "[V(4)Q(5)]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. " 01/01/2016 - "The present study shows that [V(4)Q(5)]dDAVP may complement conventional chemotherapy by modulating metastatic progression and early stages of microtumour establishment, and thus supports further preclinical testing of the compound for the management of aggressive breast cancer." 01/01/2016 - "Interestingly, [V(4)Q(5)]dDAVP plus cytotoxic agents severely impaired colony forming ability of tumour cells and inhibited breast cancer metastasis to lung. " 01/01/2016 - "Benefits of combined therapy were confirmed in the hormone-independent and metastatic F3II breast cancer model by combining [V(4)Q(5)]dDAVP with carmustine (25 mg/kg i.p.). "
2.	Neoplasms (Cancer) 12/01/2011 - "Preclinical evaluation of the anti-tumor activity of [V(4)Q(5)]dDAVP in animal models is warranted."
3.	Neoplasm Metastasis (Metastasis) 01/01/2016 - "Interestingly, [V(4)Q(5)]dDAVP plus cytotoxic agents severely impaired colony forming ability of tumour cells and inhibited breast cancer metastasis to lung. "

Related Drugs and Biologics

1.	Complement System Proteins (Complement)
2.	Paclitaxel (Taxol)
3.	Vasopressins (Vasopressin)
4.	Valine (L-Valine)
5.	Hormones (Hormone)
6.	Glutamine (L-Glutamine)
7.	Deamino Arginine Vasopressin (Desmopressin)
8.	Cytotoxins (Cytolysins)
9.	Carmustine (FIVB)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics